{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:20:34Z","timestamp":1793748034976,"version":"4.6.1"},"publisher-location":"Dordrecht","reference-count":135,"publisher":"Springer Netherlands","isbn-type":[{"value":"9789400754157","type":"print"},{"value":"9789400754164","type":"electronic"}],"license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012]]},"DOI":"10.1007\/978-94-007-5416-4_14","type":"book-chapter","created":{"date-parts":[[2012,12,5]],"date-time":"2012-12-05T18:36:12Z","timestamp":1354732572000},"page":"329-352","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":382,"title":["Alzheimer\u2019s Disease"],"prefix":"10.1007","author":[{"given":"Vanessa J.","family":"De-Paula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Radanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breno S.","family":"Diniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orestes V.","family":"Forlenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,12,6]]},"reference":[{"key":"14_CR1","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1001\/archneur.65.11.1509","volume":"65","author":"HJ Aizenstein","year":"2008","unstructured":"Aizenstein HJ, Nebes RD, Saxton JA, Price J, Mathis C, Tsopelas ND, Ziolko SK, James J, Snitz B, Houck PR (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65:1509\u20131517","journal-title":"Arch Neurol"},{"key":"14_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7:270\u2013279","journal-title":"Alzheimers Dement"},{"key":"14_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1083\/jcb.200207030","volume":"161","author":"HK Anandatheerthavarada","year":"2003","unstructured":"Anandatheerthavarada HK, Biswas GM, Robin AN, Avadhani G (2003) Mitochondrial targeting and a novel transmembrane arrest of Alzheimer\u2019s amyloid precursor protein impairs mitochondrial function in neuronal cells. J Cell Biol 161:41\u201354","journal-title":"J Cell Biol"},{"key":"14_CR4","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1001\/archneur.58.3.373","volume":"58","author":"N Andreasen","year":"2001","unstructured":"Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K (2001) Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 58:373\u2013379","journal-title":"Arch Neurol"},{"key":"14_CR5","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1006\/exnr.2000.7501","volume":"166","author":"H Arai","year":"2000","unstructured":"Arai H, Ishiguro K, Ohno H, Moriyama M, Itoh N, Okamura N, Matsui T, Morikawa Y, Horikawa E, Kohno H (2000) CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp Neurol 166:201\u2013203","journal-title":"Exp Neurol"},{"key":"14_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/mp.2008.96","volume":"14","author":"KA Bates","year":"2009","unstructured":"Bates KA, Verdile G, Li Q, Ames D, Hudson P, Masters C (2009) Clearance mechanisms of Alzheimer\u2019s amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Mol Psychiatry 14:469\u2013486","journal-title":"Mol Psychiatry"},{"key":"14_CR7","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1212\/01.WNL.0000152982.47274.9E","volume":"64","author":"DA Bennett","year":"2005","unstructured":"Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS (2005) Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology 64:834\u2013841","journal-title":"Neurology"},{"key":"14_CR8","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1212\/01.wnl.0000219668.47116.e6","volume":"66","author":"DA Bennett","year":"2006","unstructured":"Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, Wilson RS (2006) Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66:1837\u20131844","journal-title":"Neurology"},{"key":"14_CR9","first-page":"213","volume":"1","author":"K Blennow","year":"2004","unstructured":"Blennow K (2004) Cerebrospinal fluid protein biomarkers for Alzheimer\u2019s disease. NeuroRX 1:213\u2013225","journal-title":"Neuro"},{"key":"14_CR10","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S1474-4422(03)00530-1","volume":"2","author":"K Blennow","year":"2003","unstructured":"Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer\u2019s disease. Lancet Neurol 2:605\u2013613","journal-title":"Lancet Neurol"},{"key":"14_CR11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","volume":"6","author":"K Blennow","year":"2010","unstructured":"Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6:131\u2013144","journal-title":"Nat Rev Neurol"},{"key":"14_CR12","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.neurobiolaging.2006.05.006","volume":"28","author":"FH Bouwman","year":"2007","unstructured":"Bouwman FH, Schoonenboom SN, Van Der Flier WM, Van Elk EJ, Kok A, Barkhof F, Blankenstein MA, Scheltens P (2007) CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging 28:1070\u20131074","journal-title":"Neurobiol Aging"},{"key":"14_CR14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/978-3-7091-6467-9_11","volume":"53","author":"H Braak","year":"1998","unstructured":"Braak H, Braak E (1998) Evolution of neuronal changes in the course of Alzheimer\u2019s disease. J Neural Transm Suppl 53:127\u2013140","journal-title":"J Neural Transm Suppl"},{"key":"14_CR15","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.neurobiolaging.2003.12.015","volume":"25","author":"H Braak","year":"2004","unstructured":"Braak H, Tredici KD (2004) Alzheimer\u2019s disease: intraneuronal alterations precede insoluble amyloid-b formation. Neurobiol Aging 25:713\u2013718","journal-title":"Neurobiol Aging"},{"key":"14_CR16","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1146\/annurev.neuro.31.060407.125529","volume":"31","author":"DL Brody","year":"2008","unstructured":"Brody DL, Holtzman DM (2008) Active and passive immunotherapy for neurodegenerative disorders. Ann Rev Neurosci 31:175\u2013193","journal-title":"Ann Rev Neurosci"},{"key":"14_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0165-0173(00)00019-9","volume":"33","author":"L Bu\u00e9e","year":"2000","unstructured":"Bu\u00e9e L, Bussi\u00e8re T, Bu\u00e9e-Scherrer V, Delacourte A, Hof PR (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33:95\u2013130","journal-title":"Brain Res Brain Res Rev"},{"key":"14_CR18","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1093\/brain\/awl269","volume":"129","author":"K Buerger","year":"2006","unstructured":"Buerger K, Ewers M, Pirttil\u00e4 T, Zinkowski R, Alafuzoff I, Teipel SJ, DeBernardis J, Kerkman D, McCulloch C, Soininen H (2006) CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer\u2019s disease. Brain 129:3035\u20133041","journal-title":"Brain"},{"key":"14_CR19","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1523\/JNEUROSCI.18-23-09629.1998","volume":"18","author":"JD Buxbaum","year":"1998","unstructured":"Buxbaum JD, Thinakaran G, Koliatsos V, O\u2019Callahan J, Slunt HH, Price DL, Sisodia SS (1998) Alzheimer amyloid protein precursor in the rat hippocampus: transport and processing through the perforant path. J Neurosci 18:9629\u20139637","journal-title":"J Neurosci"},{"key":"14_CR20","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jalz.2011.05.2353","volume":"7","author":"C Carlson","year":"2011","unstructured":"Carlson C, Estergard W, Oh J, Suhy J, Jack CR Jr, Siemers E, Barakos J (2011) Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer\u2019s disease study cohorts from phase 3 trials of semagacestat and solanezumab. Alzheimers Dement 7:396\u2013401","journal-title":"Alzheimers Dement"},{"key":"14_CR21","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/j.1471-4159.2004.02452.x","volume":"89","author":"WP Chang","year":"2004","unstructured":"Chang WP, Koelsch G, Wong S, Downs D, Da H, Weerasena V, Gordon B, Devasamudram T, Bilcer G, Ghosh AK, Tang J (2004) In vivo inhibition of Abeta production by memapsin 2 (beta-secretase) inhibitors. J Neurochem 89:1409\u20131416","journal-title":"J Neurochem"},{"key":"14_CR22","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.2967\/jnumed.109.065284","volume":"50","author":"SR Choi","year":"2009","unstructured":"Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F (2009) Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med 50:1887\u20131894","journal-title":"J Nucl Med"},{"key":"14_CR23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nrd2896","volume":"9","author":"M Citron","year":"2010","unstructured":"Citron M (2010) Alzheimer\u2019s disease: strategies for disease modification. Nature Rev Drug Discov 9:387\u2013398","journal-title":"Nature Rev Drug Discov"},{"key":"14_CR24","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1001\/archneur.60.12.1696","volume":"60","author":"C Clark","year":"2003","unstructured":"Clark C, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris J, McKeel DW, Farlow M, Weitlauf SL (2003) Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 60:1696\u20131702","journal-title":"Arch Neurol"},{"key":"14_CR25","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/0959-4388(91)90051-8","volume":"1","author":"DW Cleveland","year":"1991","unstructured":"Cleveland DW, Hoffman PN (1991) Neuronal and glial cytoskeletons. Curr. Opin. Neurobiol 1:346\u2013353","journal-title":"Curr. Opin. Neurobiol"},{"key":"14_CR26","doi-asserted-by":"crossref","unstructured":"Consensus Report of the Working Group on: \u201cMolecular and Biochemical Markers of Alzheimer\u2019s Disease\u201d (1998) The Ronald and Nancy Reagan Research Institute of the Alzheimer\u2019s Association and the National Institute on Aging Working Group. Neurobiol Aging 19:109\u2013116","DOI":"10.1016\/S0197-4580(98)00022-0"},{"key":"14_CR27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2006.07.001","volume":"2","author":"J Cummings","year":"2006","unstructured":"Cummings J (2006) Challenges to demonstrating disease-modifying effects in Alzheimer\u2019s disease clinical trials. Challenges to demonstrating disease-modifying effects in Alzheimer\u2019s disease clinical trials. Alzheimer Dement 2:263\u2013271","journal-title":"Alzheimer Dement"},{"key":"14_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0896-6273(03)00205-8","volume":"38","author":"B Strooper","year":"2003","unstructured":"De Strooper B (2003) Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-secretase complex. Neuron 38:9\u201312","journal-title":"Neuron"},{"key":"14_CR30","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1080\/15622970701535502","volume":"9","author":"B Diniz","year":"2008","unstructured":"Diniz B, Pinto J, Forlenza OV (2008) Do CSF total tau, phosphorylated tau, and b-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer\u2019s disease? A systematic review and meta-analysis of the literature. World J Biol Psychiatry 9:172\u2013182","journal-title":"World J Biol Psychiatry"},{"key":"14_CR31","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1091\/mbc.3.10.1141","volume":"3","author":"DN Drechsel","year":"1992","unstructured":"Drechsel DN, Hyman AA, Cobb MH, Kirschner MW (1992) Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol Biol Cell 3:1141\u20131154","journal-title":"Mol Biol Cell"},{"key":"14_CR32","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.ncl.2007.03.007","volume":"25","author":"CB Eckman","year":"2007","unstructured":"Eckman CB, Eckman EA (2007) An Update on the amyloid hypothesis. Neurol Clin 25:669\u2013682","journal-title":"Neurol Clin"},{"key":"14_CR33","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1212\/01.wnl.0000244749.20056.d4","volume":"68","author":"P Edison","year":"2007","unstructured":"Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, Hotton G, Cutler D, Fox N, Kennedy A, Rossor M, Brooks DJ (2007) Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 68:501\u2013508","journal-title":"Neurology"},{"key":"14_CR34","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ana.20730","volume":"59","author":"AM Fagan","year":"2006","unstructured":"Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59:512\u2013519","journal-title":"Ann Neurol"},{"key":"14_CR35","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/archneur.64.3.noc60123","volume":"64","author":"AM Fagan","year":"2007","unstructured":"Fagan AM, Roe CM, Xiong C, Mintun MA, Morris J, Holtzman D (2007) Cerebrospinal fluid tau\/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64:343\u2013349","journal-title":"Arch Neurol"},{"key":"14_CR36","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/emmm.200900048","volume":"1","author":"AM Fagan","year":"2009","unstructured":"Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, Marcus D, Morris JC, Holtzman DM (2009) Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer\u2019s disease. EMBO Mol Med 1:371\u2013380","journal-title":"EMBO Mol Med"},{"key":"14_CR37","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.biopsych.2004.05.014","volume":"56","author":"A Fellgiebel","year":"2004","unstructured":"Fellgiebel A, Siessmeier T, Scheurich A, Winterer G, Bartenstein P, Schmidt LG, M\u00f6ller MJ (2004) Association of elevated phospho-tau levels with Alzheimer-typical 18F-fluoro-2-deoxy-D-glucose positron emission tomography findings in patients with mild cognitive impairment. Biol Psychiatry 56:279\u2013283","journal-title":"Biol Psychiatry"},{"key":"14_CR38","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1001\/archneur.65.8.1031","volume":"65","author":"AS Fleisher","year":"2008","unstructured":"Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ (2008) Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 65:1031\u20131038","journal-title":"Arch Neurol"},{"key":"14_CR39","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/1741-7015-8-89","volume":"8","author":"OV Forlenza","year":"2010a","unstructured":"Forlenza OV, Diniz BS, Gattaz WF (2010a) Diagnosis and biomarkers of predementia in Alzheimer\u2019s disease. BMC Med 8:89","journal-title":"BMC Med"},{"key":"14_CR40","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1590\/S1516-44462010005000002","volume":"32","author":"OV Forlenza","year":"2010b","unstructured":"Forlenza OV, Diniz BS, Talib LL, Radanovic M, Yassuda MS, Ojopi EB, Gattaz WF (2010b) Clinical and biological predictors of Alzheimer\u2019s disease in patients with amnestic mild cognitive impairment. Rev Bras Psiquiatr 32:216\u2013222","journal-title":"Rev Bras Psiquiatr"},{"key":"14_CR41","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1016\/j.neurobiolaging.2007.03.029","volume":"29","author":"A Forsberg","year":"2008","unstructured":"Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, Langstr\u00f6m B, Nordberg A (2008) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29:1456\u20131465","journal-title":"Neurobiol Aging"},{"key":"14_CR42","first-page":"1633","volume":"152","author":"H Funato","year":"1998","unstructured":"Funato H, Yoshimura M, Kusui K, Tamaoka A, Ishikawa K, Ohkoshi N, Namekata K, Okeda R, Ihara Y (1998) Quantitation of amyloid beta-protein (A beta) in the cortex during aging and in Alzheimer\u2019s disease. Am J Pathol 152:1633\u20131640","journal-title":"Am J Pathol"},{"key":"14_CR43","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.autrev.2005.06.007","volume":"5","author":"V Geylis","year":"2006","unstructured":"Geylis V, Steinitz M (2006) Immunotherapy of Alzheimer\u2019s disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies. Autoimmun Rev 5:33\u201339","journal-title":"Autoimmun Rev"},{"key":"14_CR44","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","volume":"64","author":"S Gilman","year":"2005","unstructured":"Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby. L, Rovira MB, Forette F, Orgogozo JM (2005) AN1792(QS-21)-201 Study Team. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64:1553\u20131562","journal-title":"Neurology"},{"key":"14_CR45","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S0006-291X(84)80190-4","volume":"120","author":"GG Glenner","year":"1984","unstructured":"Glenner GG, Wong CW (1984) Alzheimer\u2019s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120:885\u2013890","journal-title":"Biochem Biophys Res Commun"},{"key":"14_CR46","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1001\/jama.2009.1866","volume":"302","author":"RC Green","year":"2009","unstructured":"Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH (2009) Tarenflurbil Phase 3 Study Group. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 302:2557\u20132564","journal-title":"JAMA"},{"key":"14_CR47","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/sj.mp.4001473","volume":"9","author":"H Hampel","year":"2004","unstructured":"Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M (2004) Value of CSF beta-amyloid1\u201342 and tau as predictors of Alzheimer\u2019s disease in patients with mild cognitive impairment. Mol Psychiatry 9:705\u2013710","journal-title":"Mol Psychiatry"},{"key":"14_CR48","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S1474-4422(06)70355-6","volume":"5","author":"O Hansson","year":"2006","unstructured":"Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer\u2019s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5:228\u2013234","journal-title":"Lancet Neurol"},{"key":"14_CR49","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.neurobiolaging.2007.06.009","volume":"30","author":"O Hansson","year":"2009","unstructured":"Hansson O, Buchhave P, Zetterberg H, Blennow K, Minthon L, Warkentin S (2009) Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer\u2019s disease. Neurobiol Aging 30:165\u2013173","journal-title":"Neurobiol Aging"},{"key":"14_CR50","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy JA, Higgins GA (1992) Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science 256:184\u2013185","journal-title":"Science"},{"key":"14_CR51","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1007\/s00018-007-7220-x","volume":"64","author":"F Hern\u00e1ndez","year":"2007","unstructured":"Hern\u00e1ndez F, Avila J (2007) Tauopathies. Cell Mol Life Sci 64:2219\u20132233","journal-title":"Cell Mol Life Sci"},{"key":"14_CR52","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","volume":"372","author":"C Holmes","year":"2008","unstructured":"Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer. A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JAR (2008) Long-term effects of Ab42 immunisation in Alzheimer\u2019s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372:216\u2013223","journal-title":"Lancet"},{"key":"14_CR137","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neulet.2004.10.031","volume":"373","author":"A Hye","year":"2005","unstructured":"Hye A, Kerr F, Archer N, Foy C, Poppe M, Brown R, Hamilton G, Powell J, Anderton B, Lovestone S (2005) Glycogen synthase kinase-3 is increased in white cells early in Alzheimer\u2019s disease. Neurosci Lett 373:1\u20134","journal-title":"Neurosci Lett"},{"key":"14_CR53","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1124\/jpet.107.129007","volume":"323","author":"BP Imbimbo","year":"2007","unstructured":"Imbimbo BP, Del Giudice. E, Colavito D, D\u2019Arrigo A, Dalle Carbonare M, Villetti G, Facchinetti F, Volta R, Pietrini V, Baroc MF, Serneels L, De Strooper B, Leon A (2007) 1-(3\u00a2,4\u00a2-Dichloro-2-fluoro[1,1\u00a2-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer\u2019s disease without causing peripheral toxicity. J Pharmacol Exp. Ther 323:822\u2013830","journal-title":"J Pharmacol Exp. Ther"},{"key":"14_CR54","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.bbadis.2004.09.008","volume":"13","author":"K Iqbal","year":"2005","unstructured":"Iqbal K, Adel C, Chen S, Chohan MO, El-Akkad E, Gong CX, Khatoon S, Li B, Liu F, Rahman A, Tanimuk H, Grundke-Iqbal I (2005) Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 13:198\u2013210","journal-title":"Biochim Biophys Acta"},{"key":"14_CR55","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1093\/brain\/awp062","volume":"132","author":"CR Jack","year":"2009a","unstructured":"Jack CR, Lowe V, Weigand S, Wiste H, Senjem M, Knopman DS, Shiung M, Gunter J, Boeve B, Kemp B (2009a) Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer\u2019s disease: implications for sequence of pathological events in Alzheimer\u2019s disease. Brain 132:1355\u20131365","journal-title":"Brain"},{"key":"14_CR56","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","volume":"9","author":"CR Jack","year":"2009b","unstructured":"Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW (2009b) Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade. Lancet Neurol 9:119\u2013128","journal-title":"Lancet Neurol"},{"key":"14_CR57","doi-asserted-by":"publisher","first-page":"5721","DOI":"10.1242\/jcs.01558","volume":"117","author":"GV Johnson","year":"2004","unstructured":"Johnson GV, Stoothoff WH (2004) Tau phosphorylation in neuronal cell function and dysfunction. J Cell Sci 117:5721\u20139","journal-title":"J Cell Sci"},{"key":"14_CR58","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/ana.21223","volume":"63","author":"K Josephs","year":"2008","unstructured":"Josephs K, Whitwell J, Ahmed Z, Shiung M, Weigand S, Knopman D, Boeve B, Parisi J, Petersen R, Dickson D et al (2008)\u03b2-amyloid burden is not associated with rates of brain atrophy. Ann Neurol 63:204\u2013212","journal-title":"Ann Neurol"},{"key":"14_CR59","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/325733a0","volume":"325","author":"J Kang","year":"1987","unstructured":"Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, M\u00fcller-Hill B (1987) The precursor of Alzheimer\u2019s disease amyloid A4 protein resembles a cell-surface receptor. Nature 325:733\u2013736","journal-title":"Nature"},{"key":"14_CR60","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1212\/01.wnl.0000260969.94695.56","volume":"68","author":"NM Kemppainen","year":"2007","unstructured":"Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Brack A, Oikonen V, Kailaj\u03b4rvi M, Scheinin M, Viitanen M et al (2007) PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 68:1603\u20131606","journal-title":"Neurology"},{"key":"14_CR61","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"W Klunk","year":"2004","unstructured":"Klunk W, Engler H, Nordberg A, Wang Y, Blomqvist. G, Holt DP, Bergstr\u03c6m M, Savitcheva I, Huang GF, Estrada S et al (2004) Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh compound-B. Ann Neurol 55:306\u2013319","journal-title":"Ann Neurol"},{"key":"14_CR62","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/jnen\/62.11.1087","volume":"62","author":"DS Knopman","year":"2003","unstructured":"Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ, Smith GE, Dickson DW, Johnson KA, Petersen LE, McDonald WC, Braak H, Petersen RC (2003) Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 62:1087\u20131095","journal-title":"J Neuropathol Exp Neurol"},{"key":"14_CR63","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1750-3639.1993.tb00724.x","volume":"3","author":"KS Kosik","year":"1993","unstructured":"Kosik KS (1993) The molecular and cellular biology fo tau. Brain Path 3:39\u201343","journal-title":"Brain Path"},{"key":"14_CR64","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1212\/01.wnl.0000192393.05850.ec","volume":"66","author":"SV Kulandaivelu","year":"2006","unstructured":"Kulandaivelu SV, Gopal T (2006) Amyloidogenic processing of b-amyloid precursor protein in intracellular compartments. Neurology 66: S69-S73","journal-title":"Neurology"},{"key":"14_CR65","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1124\/jpet.106.112102","volume":"320","author":"DK Lahiri","year":"2007","unstructured":"Lahiri DK, Chen D, Maloney B, Holloway HW, Yu QS, Utsuki T, Giordano T, Sambamurti K, Greig NH (2007) The experimental Alzheimer\u2019s disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice. J Pharmacol Exp Ther 320:386\u2013396","journal-title":"J Pharmacol Exp Ther"},{"key":"14_CR66","doi-asserted-by":"publisher","first-page":"3922","DOI":"10.1073\/pnas.96.7.3922","volume":"96","author":"S Lammich","year":"1999","unstructured":"Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, Haass C, Fahrenholz F (1999) Constitutive and regulated alpha-secretase cleavage of Alzheimer\u2019s amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci USA 96:3922\u20133927","journal-title":"Proc Natl Acad Sci USA"},{"key":"14_CR67","doi-asserted-by":"publisher","first-page":"9319","DOI":"10.1523\/JNEUROSCI.3246-05.2005","volume":"25","author":"S Lesne","year":"2005","unstructured":"Lesne S, Kotilinek L (2005) Amyloid plaques and amyloid-b oligomers: an ongoing debate. J Neurosci 25:9319\u20139320","journal-title":"J Neurosci"},{"key":"14_CR68","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1126\/science.7638622","volume":"269","author":"E Levy-Lahad","year":"1995","unstructured":"Levy-Lahad E, Wasco W, Poorkaj P et al (1995) Candidate gene for the chromosome 1 familial Alzheimer\u2019s disease locus. Science 269:973\u2013977","journal-title":"Science"},{"key":"14_CR69","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1471-4159.2007.05064.x","volume":"104","author":"P Lichtlen","year":"2008","unstructured":"Lichtlen P, Mohajeri MH (2008) Antibody-based approaches in Alzheimer\u2019s research: safety, pharmacokinetics, metabolism, and analytical tools. J Neurochem 104:859\u2013874","journal-title":"J Neurochem"},{"key":"14_CR70","doi-asserted-by":"crossref","first-page":"5301","DOI":"10.1016\/S0021-9258(17)42989-9","volume":"259","author":"G Lindwall","year":"1984","unstructured":"Lindwall G, Cole RD (1984) Phosphorylation affects the ability of tau protein to promote microtubule assembly. J Biol Chem 259:5301\u20135305","journal-title":"J Biol Chem"},{"key":"14_CR71","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1212\/01.wnl.0000234879.82633.f3","volume":"66","author":"CF Lippa","year":"2006","unstructured":"Lippa CF, Morris JC (2006) Alzheimer neuropathology in nondemented aging: keeping mind over matter. Neurology 66:1801\u20131802","journal-title":"Neurology"},{"key":"14_CR72","first-page":"883","volume":"5","author":"S Lovestone","year":"1992","unstructured":"Lovestone S, Anderton B (1992) Cytoskeletal abnormalities in Alzheimer\u2019s disease. Curr Opin Neurol Neurosurg 5:883\u2013888","journal-title":"Curr Opin Neurol Neurosurg"},{"key":"14_CR73","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0306-4522(96)00577-5","volume":"78","author":"S Lovestone","year":"1997","unstructured":"Lovestone S, Hartley CL, Pearce J, Anderton BH (1997) The psosphorylation of tau: a critiacal stage in neurodevelopmental and neurodegenerative processes. Neuroscience 78:309\u2013324","journal-title":"Neuroscience"},{"key":"14_CR74","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/archneur.63.1.38","volume":"63","author":"WR Markesbery","year":"2006","unstructured":"Markesbery WR, Schmitt FA, Kryscio RJ, Davis DG, Smith CD, Wekstein DR (2006) Neuropathologic substrate of mild cognitive impairment. Arch Neurol 63:38\u201346","journal-title":"Arch Neurol"},{"key":"14_CR75","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1021\/jm030026b","volume":"46","author":"C Mathis","year":"2003","unstructured":"Mathis C, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk W (2003) Synthesis and evaluation of 11 C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 46:2740\u20132754","journal-title":"J Med Chem"},{"key":"14_CR76","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1001\/jama.2009.1064","volume":"302","author":"N Mattsson","year":"2009","unstructured":"Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M et al (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302:385\u2013393","journal-title":"JAMA"},{"key":"14_CR77","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1515\/cclm.2010.131","volume":"48","author":"N Mattsson","year":"2010","unstructured":"Mattsson N, Blennow. K, Zetterberg H (2010) Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer\u2019s disease: united we stand, divided we fall. Clin Chem Lab Med 48:603\u2013607","journal-title":"Clin Chem Lab Med"},{"key":"14_CR78","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jalz.2011.05.2243","volume":"7","author":"N Mattsson","year":"2011","unstructured":"Mattsson N, Andreasson U, Persson S, Arai. H, Batish SD, Bernardini S et al (2011) The Alzheimer\u2019s Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 7:386\u201395","journal-title":"Alzheimers Dement"},{"key":"14_CR79","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nrd2111","volume":"6","author":"MP Mazanetz","year":"2007","unstructured":"Mazanetz MP, Fischer PM (2007) Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nature Rev Drug Discov 6:464\u2013479","journal-title":"Nature Rev Drug Discov"},{"key":"14_CR80","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"GM McKhann","year":"1984","unstructured":"McKhann GM, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology 34:939\u2013944","journal-title":"Neurology"},{"key":"14_CR81","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman. BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7:263\u2013269","journal-title":"Alzheimers Dement"},{"key":"14_CR82","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195134759.001.0001","volume-title":"Principles of Behavioral and Cognitive Neurology","author":"M-M Mesulam","year":"2000","unstructured":"Mesulam M-M (2000) Aging, Alzheimer\u2019s Disease, and Dementia. Clinical and neuropathological perspectives. In: Mesulam M-M (ed) Principles of Behavioral and Cognitive Neurology, 2nd edn. Oxford University, New York","edition":"2nd edn"},{"key":"14_CR83","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1212\/WNL.41.4.479","volume":"41","author":"SS Mirra","year":"1991","unstructured":"Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The Consortium to Establish a Registry for Alzheimer\u2019s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer\u2019s disease. Neurology 41:479\u2013486","journal-title":"Neurology"},{"key":"14_CR117","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1471-4159.2007.05064.x","volume":"104","author":"MH Mohajeri","year":"2008","unstructured":"Mohajeri MH (2008) Antibody-based approaches in Alzheimer\u2019s research: safety, pharmacokinetics, metabolism, and analytical tools. J Neurochem 104:859\u2013874","journal-title":"J Neurochem"},{"key":"14_CR84","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s004060050027","volume":"248","author":"HJ Moller","year":"1998","unstructured":"Moller HJ, Graeber MB (1998) The case described by Alois Alzheimer in 1911. Historical and conceptual perspectives based on the clinical record and neurohistological sections. Eur Arch Psychiatry Clin Neurosci 248:111\u2013122","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"14_CR85","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/35050116","volume":"408","author":"D Morgan","year":"2000","unstructured":"Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer\u2019s disease. Nature 408:982\u2013985","journal-title":"Nature"},{"key":"14_CR86","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/S0002-9440(10)64847-X","volume":"157","author":"M Morishima-Kawashima","year":"2000","unstructured":"Morishima-Kawashima M, Oshima N, Ogata H, Yamaguchi H, Yoshimura M, Sugihara S, Ihara Y (2000) Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid beta-protein accumulation in the human brain. Am J Pathol 157:2093\u20132099","journal-title":"Am J Pathol"},{"key":"14_CR87","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.1925564","volume":"254","author":"J Murrell","year":"1991","unstructured":"Murrell J, Farlow M, Ghetti B, Benson MD (1991) A mutation in the amyloid precursor protein associated with hereditary Alzheimer\u2019s disease. Science 254:97\u201399","journal-title":"Science"},{"key":"14_CR88","unstructured":"National Institute of Aging\/Alzheimer\u2019s Association guidelines for the Neuropathological Assessment of AD (2011) http:\/\/www.alz.org\/ documents. Accessed 17 Sept 2011"},{"key":"14_CR89","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/nm840","volume":"9","author":"JA Nicoll","year":"2003","unstructured":"Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nature Med 9:448\u2013452","journal-title":"Nature Med"},{"key":"14_CR91","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1365-2990.2006.00767.x","volume":"32","author":"T Oide","year":"2006","unstructured":"Oide T, Kinoshita T, Arima K (2006) Regression stage senile plaques in the natural course of Alzheimer\u2019s disease. Neuropathol Appl Neurobiol 32:539\u2013556","journal-title":"Neuropathol Appl Neurobiol"},{"key":"14_CR92","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/WNL.0b013e3181b23564","volume":"73","author":"A Okello","year":"2009","unstructured":"Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Nagren K, Bullock R, Walker Z, Kennedy A, Fox NC, Rossor MN, Rinne JO, Brooks DJ (2009) Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 73:754\u2013760","journal-title":"Neurology"},{"key":"14_CR93","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","volume":"61","author":"JM Orgogozo","year":"2003","unstructured":"Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61:46\u201354","journal-title":"Neurology"},{"key":"14_CR94","doi-asserted-by":"publisher","first-page":"537","DOI":"10.2165\/11315770-000000000-00000","volume":"26","author":"F Panza","year":"2009","unstructured":"Panza F, Solfrizzi V, Frisardi V, Capurso C, D\u2019Introno A, Colacicco AM, Vendemiale G, Capurso A, Imbimbo BP (2009) Disease-modifying approach to the treatment of Alzheimer\u2019s disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators. Drugs Aging 26:537\u2013555","journal-title":"Drugs Aging"},{"key":"14_CR95","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1001\/jama.296.3.327","volume":"296","author":"ER Peskind","year":"2006","unstructured":"Peskind ER, Ge LI, Shofer J, Quinn JF, Kaye JA,2006 Time will be of the essence in treating Alzheimer disease. JAMA 296:327\u2013329","journal-title":"JAMA"},{"key":"14_CR96","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jns.2004.09.007","volume":"226","author":"GJ Petot","year":"2004","unstructured":"Petot GJ, Friedland RP (2004) Lipids, diet and Alzheimer disease: an extended summary. J Neurol Sci 226:31\u201333","journal-title":"J Neurol Sci"},{"key":"14_CR97","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.febslet.2004.06.025","volume":"570","author":"M Recuero","year":"2004","unstructured":"Recuero M, Serrano E, Bullido MJ, Valdivieso F (2004) Abeta production as consequence of cellular death of a human neuroblastoma overexpressing APP. FEBS Lett 570:114\u2013118","journal-title":"FEBS Lett"},{"key":"14_CR98","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0009-8981(01)00573-3","volume":"310","author":"H Reiber","year":"2001","unstructured":"Reiber H (2001) Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 310:173\u2013186","journal-title":"Clin Chim Acta"},{"key":"14_CR99","doi-asserted-by":"publisher","first-page":"6820","DOI":"10.1073\/pnas.0900345106","volume":"106","author":"EM Reiman","year":"2009","unstructured":"Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JB et al (2009) Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer\u2019s disease. Proc Natl Acad Sci USA 106:6820\u20136825","journal-title":"Proc Natl Acad Sci USA"},{"key":"14_CR100","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1001\/archneurol.2010.19","volume":"67","author":"DM Rentz","year":"2010","unstructured":"Rentz DM, Locascio JJ, Becker JA, Moran EK, Eng E, Buckner RL, Sperling RA, Johnson KA (2010) Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol 67:353\u2013364","journal-title":"Ann Neurol"},{"key":"14_CR101","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1212\/WNL.0b013e3181d3e3e9","volume":"74","author":"SM Resnick","year":"2010","unstructured":"Resnick SM, Sojkova J, Zhou Y, An Y, Ye W, Holt DP, Dannals RF, Mathis C, Klunk W, Ferrucci L et al (2010) Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology 74:807\u2013815","journal-title":"Neurology"},{"key":"14_CR102","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/13813450701572288","volume":"113","author":"V Rhein","year":"2007","unstructured":"Rhein V, Eckert A (2007) Effects of Alzheimer\u2019s amyloid-beta and tau protein on mitochondrial function--role of glucose metabolism and insulin signalling. Arch Physiol Biochem 113:131\u2013141","journal-title":"Arch Physiol Biochem"},{"key":"14_CR103","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/archneur.59.11.1729","volume":"59","author":"M Riemenschneider","year":"2002","unstructured":"Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A (2002) Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 59:1729\u20131734","journal-title":"Arch Neurol"},{"key":"14_CR104","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","volume":"9","author":"JO Rinne","year":"2010","unstructured":"Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez MLS, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M (2010) 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer\u2019s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9:363\u2013372","journal-title":"Lancet Neurol"},{"key":"14_CR105","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1136\/jnnp.57.4.419","volume":"57","author":"GW Roberts","year":"1994","unstructured":"Roberts GW, Gentleman SM, Lynch A, Murray L, Landon M, Graham DI (1994) Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer\u2019s disease. J Neurol Neurosurg Psychiat 57:419\u2013425","journal-title":"J Neurol Neurosurg Psychiat"},{"key":"14_CR106","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1212\/01.wnl.0000251303.50459.8a","volume":"68","author":"CM Roe","year":"2007","unstructured":"Roe CM, Xiong C, Miller JP, Morris JC (2007) Education and Alzheimer disease without dementia: support for the cognitive reserve hypothesis. Neurology 68:223\u2013228","journal-title":"Neurology"},{"key":"14_CR107","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3233\/JAD-2011-101809","volume":"24","author":"AE Roher","year":"2011","unstructured":"Roher AE, Maarouf CL, Daugs ID, Kokjohn TA, Hunter JM, Sabbagh MN, Beach TG (2011) Neuropathology and amyloid-b spectrum in a bapineuzumab immunotherapy recipient. J Alzheimers Dis 24:315\u2013325","journal-title":"J Alzheimers Dis"},{"key":"14_CR108","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S1474-4422(08)70001-2","volume":"7","author":"CC Rowe","year":"2008","unstructured":"Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O\u2019Keefe G, Tochon-Danguy H, Chan G, Berlangieri SU, Jones G et al (2008) Imaging of amyloid beta in Alzheimer\u2019s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 7:129\u2013135","journal-title":"Lancet Neurol"},{"key":"14_CR109","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","volume":"73","author":"S Salloway","year":"2009","unstructured":"Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M, Bapineuzumab (2009) 201 Clinical Trial Investigators. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73:2061\u20132070","journal-title":"Neurology"},{"key":"14_CR110","doi-asserted-by":"publisher","first-page":"e2718","DOI":"10.1371\/journal.pone.0002718","volume":"3","author":"S Sanz-Blasco","year":"2008","unstructured":"Sanz-Blasco S, Valero RA, Rodr\u00edguez-Crespo I, Villalobos C, N\u00fa\u00f1ez L (2008) Mitochondrial Ca2+ overload underlies Abeta oligomers neurotoxicity providing an unexpected mechanism of neuroprotection by NSAIDs. PLoS ONE 3:e2718","journal-title":"PLoS ONE"},{"key":"14_CR111","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1076\/jcen.25.5.625.14576","volume":"25","author":"N Scarmeas","year":"2003","unstructured":"Scarmeas N, Stern Y (2003) Cognitive reserve and lifestyle. J Clin Exp Neuropsychol 25:625\u2013633","journal-title":"J Clin Exp Neuropsychol"},{"key":"14_CR112","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.mehy.2006.02.023","volume":"1","author":"HP Schmitt","year":"2006","unstructured":"Schmitt HP (2006) Protein ubiquitination, degradation and the proteasome in neuro-degenerative disorders: No clear evidence for a significant pathogenetic role of proteasome failure in Alzheimer disease and related disorders. Medical Hypotheses 1:311\u2013317","journal-title":"Medical Hypotheses"},{"key":"14_CR113","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3233\/JAD-2009-1227","volume":"18","author":"JA Schneider","year":"2009a","unstructured":"Schneider JA, Aggarwal NT, Barnes L, Boyle P, Bennett DA (2009a) The neuropathology of older persons with and without dementia from community versus clinic cohorts. J Alzheimers Dis 18:691\u2013701","journal-title":"J Alzheimers Dis"},{"key":"14_CR114","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/ana.21706","volume":"66","author":"JA Schneider","year":"2009b","unstructured":"Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA (2009b) Mixed pathologies in probable Alzheimer\u2019s disease and mild cognitive impairment. Ann Neurol 66:200\u2013208","journal-title":"Ann Neurol"},{"key":"14_CR115","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/scientificamerican1191-68","volume":"265","author":"DJ Selkoe","year":"1991","unstructured":"Selkoe DJ (1991) Amyloid protein and Alzheimer\u2019s disease. Sci Am 265:68\u201371, 74\u201376, 78","journal-title":"Sci Am"},{"key":"14_CR116","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/brain\/awq056","volume":"133","author":"A Serrano-Pozo","year":"2010","unstructured":"Serrano-Pozo A, William CM, Ferrer I, Uro-Coste E, Delisle MB, Maurage CA, Hock C, Nitsch RM, Masliah E, Growdon JH, Frosch MP, Hyman BT (2010) Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain 133:1312\u20131327","journal-title":"Brain"},{"key":"14_CR138","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1007\/PL00012495","volume":"39","author":"N Shahani","year":"2002","unstructured":"Shahani N, Brandt R (2002) Functions and malfunctions of the tau proteins. Cell Mol Life Sci 39:1668\u20131680","journal-title":"Cell Mol Life Sci"},{"key":"14_CR118","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ana.21610","volume":"65","author":"L Shaw","year":"2009","unstructured":"Shaw L, Vanderstichele H, Knapik-Czajka M, Clark C, Aisen P, Petersen R, Blennow K, Soares H, Simon A, Lewczuk P et al (2009) Cerebrospinal fluid biomarker signature in Alzheimer\u2019s disease neuroimaging initiative subjects. Ann Neurol 65:403\u2013413","journal-title":"Ann Neurol"},{"key":"14_CR119","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/375754a0","volume":"375","author":"R Sherrington","year":"1995","unstructured":"Sherrington R, Rogaev EI, Liang Y et al (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer\u2019s disease. Nature 375:754\u2013760","journal-title":"Nature"},{"key":"14_CR120","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1212\/01.WNL.0000198762.41312.E1","volume":"66","author":"ER Siemers","year":"2006","unstructured":"Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, Tariot P, Zoulnouni P, Galvin JE, Holtzman DM, Knopman DS, Satterwhite J, Gonzales C, Dean RA, May PC (2006) Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 66:602\u2013604","journal-title":"Neurology"},{"key":"14_CR121","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1056\/NEJMoa054625","volume":"355","author":"GW Small","year":"2006","unstructured":"Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, Burggren AC, Cole GM, Vinters H et al (2006) PET of brain amyloid and tau in mild cognitive impairment. New Engl J Med 355:2652\u20132663","journal-title":"New Engl J Med"},{"key":"14_CR122","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/ana.21208","volume":"62","author":"JA Sonnen","year":"2007","unstructured":"Sonnen JA, Larson EB, Crane PK, Haneuse S, Li G, Schellenberg GD, Craft S, Leverenz JB, Montine TJ (2007) Pathological correlates of dementia in a longitudinal, population based sample of aging. Ann Neurol 62:406\u2013413","journal-title":"Ann Neurol"},{"key":"14_CR123","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7:280\u2013292","journal-title":"Alzheimers Dement"},{"key":"14_CR124","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1001\/jama.289.16.2094","volume":"289","author":"T Sunderland","year":"2003","unstructured":"Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH et al (2003) Decreased beta-amyloid1\u201342 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289:2094\u20132103","journal-title":"JAMA"},{"key":"14_CR125","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.neurobiolaging.2006.06.021","volume":"28","author":"RH Swerdlow","year":"2007a","unstructured":"Swerdlow RH (2007a) Is aging part of Alzheimer\u2019s disease, or is Alzheimer\u2019s disease part of aging? Neurobiol Aging 28:1465\u20131480","journal-title":"Neurobiol Aging"},{"key":"14_CR126","first-page":"347","volume":"2","author":"RH Swerdlow","year":"2007b","unstructured":"Swerdlow RH (2007b) Pathogenesis of Alzheimer\u2019s disease. Clin Interv Aging 2:347\u2013359","journal-title":"Clin Interv Aging"},{"key":"14_CR127","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/archneurol.2008.596","volume":"66","author":"T Tapiola","year":"2009","unstructured":"Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttil\u00e4 T (2009) Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66:382\u2013389","journal-title":"Arch Neurol"},{"key":"14_CR128","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","volume":"58","author":"DR Thal","year":"2002","unstructured":"Thal DR, Rub U, Orantes M, Braak H (2002) Phases of Abeta-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791\u20131800","journal-title":"Neurology"},{"key":"14_CR129","first-page":"449","volume":"144","author":"JQ Trojanowski","year":"1994","unstructured":"Trojanowski JQ, Lee VM, Dawbarn D, Allen SJ (1994) The kinase connection in Paired helical filament tau in Alzheimer\u2019s disease. Neurobiology of Alzheimer\u2019s disease. Am J Pathol 144:449\u2013453","journal-title":"Am J Pathol"},{"key":"14_CR130","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/j.neurobiolaging.2006.07.001","volume":"28","author":"LA Tupler","year":"2007","unstructured":"Tupler LA, Krishnan KR, Greenberg DL, Marcovina SM, Payne ME, MacFall JR, Charles HC, Doraiswamy PM (2007) Predicting memory decline in normal elderly: genetics, MRI, and cognitive reserve. Neurobiol Aging 28:1644\u20131656","journal-title":"Neurobiol Aging"},{"key":"14_CR131","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/j.1471-4159.2007.04809.x","volume":"103","author":"MN Vieira","year":"2007","unstructured":"Vieira MN, Forny-Germano L, Saraiva LM, Sebollela A, Martinez AM, Houzel JC, De Felice FG, Ferreira ST (2007) Soluble oligomers from a non-disease related protein mimic Abeta-induced tau hyperphosphorylation and neurodegeneration. J Neurochem 103:736\u201348","journal-title":"J Neurochem"},{"key":"14_CR132","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.neuropsychologia.2008.02.008","volume":"46","author":"V Villemagne","year":"2008","unstructured":"Villemagne V, Pike KE, Darby D, Maruff P, Savage G, Ackermann U, Cowie TF, Currie, J, Chan, SG et al (2008) Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer\u2019s disease. Neuropsychologia 46:1688\u20131697","journal-title":"Neuropsychologia"},{"key":"14_CR133","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/clpt.2009.77","volume":"86","author":"JA Wagner","year":"2009","unstructured":"Wagner JA (2009) Biomarkers: principles, policies, and practice. Clin Pharmacol Ther 86:3\u20137","journal-title":"Clin Pharmacol Ther"},{"key":"14_CR134","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1460-9568.2006.05226.x","volume":"25","author":"JZ Wang","year":"2007","unstructured":"Wang JZ, Grundke-Iqbal I, Iqbal K (2007) Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci 25:59\u201368","journal-title":"Eur J Neurosci"},{"key":"14_CR135","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1001\/jama.287.6.742","volume":"287","author":"RS Wilson","year":"2002","unstructured":"Wilson RS, Mendes de Leon CF, Barnes LL, Schneider JA, Bienias JL, Evans DA, Bennett DA (2002) Participation in cognitively stimulating activities and risk of incident AD. JAMA 287:742\u2013748","journal-title":"JAMA"},{"key":"14_CR136","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/15622970510029786","volume":"6","author":"J Wiltfang","year":"2005","unstructured":"Wiltfang J, Lewczuk P, Riederer P, Granblatt E, Hock C, Scheltens P, Hampel H, Vanderstichele H, Iqbal K, Galasko D et al (2005) Consensus paper of the WFSBP task force on biological markers of dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. World J Biol Psychiatry 6:69\u201384","journal-title":"World J Biol Psychiatry"}],"container-title":["Subcellular Biochemistry","Protein Aggregation and Fibrillogenesis in Cerebral and Systemic Amyloid Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-94-007-5416-4_14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T18:32:37Z","timestamp":1714674757000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-94-007-5416-4_14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"ISBN":["9789400754157","9789400754164"],"references-count":135,"URL":"https:\/\/doi.org\/10.1007\/978-94-007-5416-4_14","relation":{},"ISSN":["0306-0225"],"issn-type":[{"value":"0306-0225","type":"print"}],"subject":[],"published":{"date-parts":[[2012]]},"assertion":[{"value":"6 December 2012","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}